GRCL News and Press, Gracell Biotechnologies Inc. From 12/26/23

2023-12-26 05:24:51 ET U.S. stock future on Tuesday edged higher on Tuesday to start the holiday-shortened week. The major averages are expected to extend their winning streak until the end of the year, as further signs of cooling US inflation reinforced bets that the Federal R...

2023-12-26 03:42:42 ET More on AstraZeneca, Gracell Biotechnologies: AstraZeneca: A $1.1B Shot In The Arm From Icosavax Acquisition AstraZeneca Pays Hefty Price For Chinese Weight-Loss Drug FDA approves AstraZeneca, Ionis drug for ATTRv-PN Gracell gain...

Includes clinical-stage autologous BCMA/CD19 CAR-T therapy targeting haematologic malignancies and autoimmune diseases, and proprietary cell therapy manufacturing platform AstraZeneca has entered into a definitive agreement to acquire Gracell Biotechnologies Inc. (Gracell, NASDAQ: GRC...

Expands clinical development of GC012F in rSLE following FDA IND clearance for Phase 1/2 trial in the United States Gracell is pioneering use of a CD19/BCMA dual-targeted CAR-T cell therapy in rSLE, aiming for deeper and wider depletion of disease-causing antibody secreting cells and B-ce...

Minimal residual disease negativity (MRD-) observed in all treated patients in the ongoing study, with 95% (21/22) achieving stringent complete response (sCR) through a median follow-up of 18.8 months GC012F is a FasTCAR-enabled B-cell maturation antigen (BCMA) and CD19 dual-targeting a...

2023-12-03 04:30:00 ET Summary LianBio, a Princeton-Shanghai in-licensing company, received a $465 million buyout offer from Tang Capital Management. Perpetual Medicines, a Shanghai-Boston AI startup, closed an $8 million seed financing to advance its peptide drug discovery platfo...

2023-11-27 13:29:09 ET More on Gracell Biotechnologies Gracell Biotechnologies Inc. (GRCL) Q3 2023 Earnings Call Transcript Gracell Biotechnologies: A CAR-T Company Flying Under Your Radar Gracell Biotechnologies Q3 GAAP EPS of -$0.51 misses by $0.38 Gracell ...

Gracell is pioneering use of a CD19/BCMA dual-targeted CAR-T cell therapy in refractory systemic lupus erythematosus, aiming for deeper and wider depletion of disease-causing antibody secreting cells and B-cells FasTCAR-T GC012F has demonstrated deep responses and a favorable safety pro...

2023-11-24 09:46:18 ET More on Health Care Select Sector Ideal Pairs Trade Into 2024: Health Vs. Hype: Capitalizing On A Therapeutic Turn And A Tech Tumble Health Care Select Sector Fund ETF: Riding The Healthcare Boom September Labor Report Preview: Full Employment ...

Presentation to focus on application of next-generation CAR-T cell therapy technologies for treatment of autoimmune disease Gracell to highlight translational research supporting CD19/BCMA dual-targeting approach in the treatment of systemic lupus erythematosus (SLE) SAN DIEGO and S...